2023-08-22 06:43:37
Marketed under the name Abrysvo, Pfizer’s vaccine once morest bronchiolitis should protect babies during their first six months of life.
On Monday, US health authorities authorized for the first time a vaccine administered to pregnant women with the aim of protect babies once morest bronchiolitisa potentially dangerous respiratory infection, especially for toddlers.
The vaccine from pharmaceutical giant Pfizer, marketed as Abrysvotargets the respiratory syncytial virus (RSV), which can cause, in its most severe forms, pneumonia and bronchiolitis.
The United States records between 58,000 and 80,000 virus-related hospitalizations in children under 5 each year, and 100 to 300 deaths.
The vaccine, authorized for pregnant women between 32 and 36 weeks of gestational age, will protect children during their first six months of life thanks to antibodies transmitted by the mother.
Soon in Europe?
This same vaccine was also approved in July by the European Medicines Agency (EMA), but the European Commission must now decide on its marketing authorization within the European Union.
Outbreaks of RSV, a highly contagious virus, are seasonal. Last winter, hospitals were stormed on both sides of the Atlantic in the face of an epidemic of impressive magnitude.
The United States records every year between 58,000 and 80,000 virus-related hospitalizations in children under 5, and 100 to 300 deaths, according to the Centers for Disease Control and Prevention. It is the leading cause of hospitalization for toddlers in the country.
1692687096
#authorizes #vaccine #pregnant #women #bronchiolitis #babies
